LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 107 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,977 | -16.3% | 15,235 | 0.0% | 0.00% | – |
| Q2 2023 | $21,481 | +26.4% | 15,235 | +2.0% | 0.00% | – |
| Q3 2022 | $17,000 | -73.8% | 14,937 | -63.6% | 0.00% | – |
| Q2 2022 | $65,000 | -7.1% | 41,065 | -9.1% | 0.00% | – |
| Q1 2022 | $70,000 | -63.7% | 45,159 | -42.6% | 0.00% | – |
| Q4 2021 | $193,000 | -38.3% | 78,742 | -36.6% | 0.00% | – |
| Q3 2021 | $313,000 | -14.7% | 124,219 | -3.5% | 0.00% | – |
| Q2 2021 | $367,000 | +4487.5% | 128,767 | +1185.7% | 0.00% | – |
| Q1 2020 | $8,000 | -27.3% | 10,015 | -12.4% | 0.00% | – |
| Q3 2019 | $11,000 | – | 11,427 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |